Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Schizophrenia Therapy
Reports outline schizophrenia therapy research from Nova Southeastern University, College of Pharmacy
November 9th, 2008
New research, 'Paliperidone extended-release for the treatment of schizophrenia,' is the subject of a report. According to a study from the United States, "Paliperidone, the major active metabolite of risperidone (9-hydroxyrisperidone), is a second-generation antipsychotic that was recently approved by the United States Food and Drug Administration for treatment of acute schizophrenia and for maintenance treatment of schizophrenia. We performed a literature search of PreMEDLINE, MEDLINE, and International Pharmaceutical Abstracts from 1966-October 2007 to review the available data on the pharmacology, pharmacokinetics, clinical evidence, and safety and tolerability profile of paliperidone...
Source: Medical Letter on the CDC & FDA (2008-11-09)
|
